Higher sensitivity of the PCR-SSCP technique than the immunohistochemical technique for the detection of mutation in the exons 5 and 6 of the p53 gene in breast cancer;Mayor sensibilidad de la técnica de RCP-SSCP frente a la inmunohistoquímica para la detección de mutaciones en los exones 5 y 6 del gen p53 en el cáncer de mama

Medicina Clinica

Volumn 106, Issue 19, 1996, Pages 721-724

  Duenas Gonzalez A ^a,b   Cruz Hernandez J J ^b   Abad Hernandez M M ^b   Ramos, M ^b   Gonzalez Sarmiento R ^a,c  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ARTICLE; BREAST TUMOR; COMPARATIVE STUDY; EXON; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SINGLE STRAND CONFORMATION POLYMORPHISM;

BASE SEQUENCE; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; EXONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; SENSITIVITY AND SPECIFICITY;

EID: 0030592081     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K et al. Mutations in the p53 gene occur in diverse tumours types. Nature (Lond) 1989, 342. 705-708.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC p53 mutations in human cancers. Science 1991, 253: 49-53.
3. Vogelstein B Cancer A. A deadly inheritance. Nature (Lond) 1990; 348: 581-682.
4. Brunet J, Alonso MC, Ojeda B Cancer de mama hereditario bases genéticas y características clínicas. Med Clin (Barc) 1994; 103: 623-627
5. Levine AJ. Mommand J, Finlay CA The p53 tumor suppressor gene Nature (Lond) 1991; 351 453-456
6. Rotter V, Prokocimer M p53 and human malignancies Adv Cancer Res 1991, 57: 257-272
7. Oren M p53: The ultimate tumor suppressor gene? FASEB J 1992; 6 3 169-3 176.
8. Montermar M Biochemical properties of the growth suppressor oncoprotein p53. Oncogene 1992; 7: 1 673-1 680
9. Vogelstein B, Kinzler KW. p53 function and disfunction Cell 1992; 70: 523-526.
10. Hinds PW, Weinberg RA. Tumor suppressor genes Curr Opin Gen Devel 1994; 4: 135-141.
11. Lane DP. A death in the life of p53 Nature (Lond) 1993; 362: 786-787.
12. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986; 6. 1.379-1.385.
13. Deng G, Chen L-C, Schott DR, Thor A, Bhargava V, Ljung B-M et al Loss of heterozygosity and p53 mutations in breast cancer Cancer Res 1994; 54. 499-505.
14. Moll UM, Riou G, Levine AJ Two distintic mechanisms after p53 in breast cancer: Mutation and nuclear exclusion Proc Natl Acad Sci USA 1992; 89 7.262-7.266.
15. Sasa M, Kondo K, Komaki K, Morimoto T, Monden Y p53 alteration correlates with negative ER, negative PgR and high histological grade in breast cancer. J Surg Oncol 1994; 56: 46-50.
16. Isola J, Visakorpi T, Holli K, Kallioniemi O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer. J Natl Cancer Inst 1992; 84 1 109-1 114.
17. Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E et al. Accumulation of p53 tumour suppressor gene protein: An independent marker of prognosis in breast cancer J Natl Cancer Inst 1992; 84: 845-855.
18. Allred DC, Clarc GM, Elledge R, Fuqua SAW, Brown RW, Chamness GC et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206.
19. Silverstrini R, Benini E, Daidone MG, Venerosi D, Boracchi P, Cappelleti V et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 965-970
20. Greenblatt MS, Bennett WP, Hollstein M, Harris CC Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 1994; 54: 4.855-4.878.
21. Estivill X, Nunes V, Gallano P La genética molecular en la investigación y el diagnóstico de la patología humana Med Clin (Barc) 1990; 94: 541-547.
22. Jones PA, Buckley JD, Henderson BE, Ross RK, Pike MC. From gene to carcinogen a rapidly evolving field in molecular epidemiology. Cancer Res 1991; 51: 3 617-3 620
23. Sánchez Garcia I, Martín Seisdedos C, Pérez Grande R, Corral de la Calle J, Rodríguez Arias C, González Sarmiento R Análisis comparative de dos métodos de extracción de ADN. Sangre (Barc) 1990, 35: 405-407
24. Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989; 86: 2.766-2.770.
25. Bourn D, Carter SA, Mason S, Gareth D, Evans R, Strachan T. Germline mutations in the neurofibromatosis type 2 tumour suppressor gene. Hum Mol Genet 1994, 3: 813-816.
26. Sambrook J, Fritsch EF, Maniatis T Molecular cloning a laboratory manual. Nueva York Cold Spring Harbor Laboratory, 1989, 1. 53-89.
27. Sambrook J, Fritsch EF, maniatis T. Molecular cloning, a laboratory manual Nueva York Cold Spring Harbor Laboratory, 1989; 13: 42-58
28. Chen LC, Neubauer A, Kurisu W, Waldman FM, Ljung BM, Goodson W et al Loss of heterozigosity on the short arm of chromosome 17 is asso- ciated with high proliferative capacity and DNA aneuploidy in primary human breast cancer. Proc Natl Acad Sci USA 1991; 88: 3.847-3.851.
29. Sommer SS, Cunningham J, McGovern RM, Saitoh S, Schroeder JJ, Wold EL et al. Pattern of p53 gene mutations in breast cancer of women of the midwestern United States. J Natl Cancer Inst 1992; 84: 246-252.
30. Coles C, Condie A, Chetty U, Steel M, Evans HJ, Prosser J. p53 mutations in breast cancer Cancer Res 1992; 52: 5.291-5.298.
31. Saitoh S, Cunningham J, De Vries EGM, McGovern RM, Schroeder J, Hartman A et al. p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis. Oncogene 1994; 9: 2.869-2 875
32. Hayashi K. PCR-SSCP: a method for detection of mutations. GATA 1992, 9. 73-79.
33. Runnebaum IG, Mahalakshmi N, Bowman M, Soto D, Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 1991; 88: 10.657-10.661.
34. Osborne RJ, Merlo GR, Mitsudomi T, Venesio T, Liscia D, Cappa ADM et al. Mutations in the p53 gene in primary human breast cancer. Cancer Res 1991; 51: 6.194-6.198.
35. Eckert KA, Kunkel TA The fidelity of DNA polymerases used in the polymerase chain reactions En: McPherson MJ, Quirke P, Taylor GR, editores. PCR: A practical approach. Nueva York: Oxford University Press, 1991, 225-245.
36. Hartmann A, Blaszyk H, McGovern RM, Schroeder JJ, Cunningham J, De Vries EMG et al. p53 gene mutations inside and outside of exons 5-8 the patterns differ in breast and other cancers Oncogene 1995; 10: 681-688